Directorate Changes
Updated : 07:06
For immediate release | 8 November 2018 |
Evgen Pharma plc
("Evgen" or "the Company")
Directorate Changes
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the appointment with immediate effect of Susan Clement-Davies, a highly experienced investment banker, as a Non-Executive Director. Simultaneously, Marc d'Abbadie, a Non-Executive Director and representative of one of the Company's early stage investors, will step down from the Board.
Susan has more than 25 years of capital markets and investment banking experience gained at banks including Bank of Tokyo (now MUFG Bank), BZW (now Barclays) and Citigroup. She worked as a managing director at Torreya Partners LLC, a global investment bank focused on life sciences, from 2014 until earlier this year. Susan's charitable work includes positions on the fund-raising committees of the Institute of Cancer Research and Great Ormond Street Hospital.
Barry Clare, Evgen's Chairman, said: "I'm delighted to welcome Susan Clement-Davies to Evgen's Board. Her extensive investment banking and life sciences experience will be of great value to the Company as we prepare for the commercialisation of our product pipeline. On behalf of the Board, I would like to extend our thanks to Marc d'Abbadie for his support and guidance both before and after Evgen's AIM flotation. We wish him well for the future."
Susan Elizabeth Clement-Davies (née Lewis) is 56 years of age. There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
Enquiries:
Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO | c/o +44 (0) 20 7466 5000
| |
Buchanan Mark Court, Sophie Wills, Tilly Abraham | +44 (0) 20 7466 5000
| |
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney (Corporate Finance) Rob Rees (Corporate Broking)
| +44 (0) 20 3861 6625 | |
WG Partners LLP Nigel Barnes, Claes Spång | +44 (0) 20 3705 9330 | |
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.